CEP170B

Across TCGA pan-cancer cohorts, CEP170B mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CEP170B data layer compared with 19 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher CEP170B mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CEP170B expression acts as an unfavorable survival marker, although some lineages such as UCEC and PDAC show a favorable association.

LUAD, UCEC, and PDAC are the cancer types where CEP170B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Tertile	II,III,IV	0.297	0.673	.008	12	view →
UCEC	DFS	Tertile	All	1.000	0.850	.008	6	view →
PDAC	OS	Median	II,III,IV	0.885	0.798	.018	5	view →
CCRCC	OS	Median	All	0.994	0.895	.029	2	view →
GBM	DFS	Median	All	0.840	0.651	.041	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CEP170B–LUAD (DFS)

Open the LUAD breakdown →